38388-19-1

Usage

Uses

Used in Cancer Therapy:
Guneribone is used as an anti-cancer agent for its ability to inhibit the growth and spread of cancer cells. It achieves this by inducing apoptosis and disrupting signaling pathways involved in cell proliferation.
Used in Inflammation Management:
Guneribone is used as an anti-inflammatory agent for its strong effects in suppressing the production of pro-inflammatory cytokines and enzymes, thereby helping to manage inflammation.
Used in Antibacterial Treatments:
Guneribone is used as a potential antibiotic for its ability to inhibit the growth of antibiotic-resistant bacteria, suggesting its potential in the development of novel antibiotics.
Used in Pharmaceutical Research:
Guneribone is used as a research compound for the development of new therapeutic agents for various diseases, given its diverse pharmacological properties and potential applications in medicine.

InChI:InChI=1/C22H34O/c1-14(2)18-7-8-19-17-6-5-15-13-16(23)9-11-21(15,3)20(17)10-12-22(18,19)4/h13-14,17-20H,5-12H2,1-4H3/t17-,18+,19-,20-,21-,22+/m0/s1

Upstream product

• 62015-52-5 20-Methyl-4,5-seco-pregnan-3,5-dion 
• 1042-59-7 20-methylpregn-5-en-3β-ol 
• 83872-45-1 (20S)-(20-Methyl-5-pregnen-3β,21-diol)-21-p-toluolsulfonat 
• 62008-74-6 (+/-)-20-Methyl-4,5-seco-14β,17α-pregnan-3,5-dion 
• 62008-74-6 (+/-)-20-Methyl-4,5-seco-14α,17β-pregnan-3,5-dion 
• 17879-91-3 (3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-(prop-1-en-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol 
• 1474-14-2 3β-acetoxybisnor-5-cholenic acid 
• 10162-98-8 (20S)-20-methyl-pregnene-(5)-diol-(3β.21) 

Relevant academic research and scientific papers

Synthesis of (+/-)-20-Methylpregn-4-en-3-one and (+/-)-20-Methyl-14β,17α-pregn-4-en-3-one via Ionic Cyclization of a Tetraenol with Preformed "Ring C"

The acid catalyzed cyclization of the polyolefinic substrates II and III was investigated.Only tetraenol II could be induced to undergo twofold bond formation to produce the A-nor-pregn-3(5),8(14)-diene derivatives 11a/11b, epimeric at C-17.The cyclization substrate was synthesized, involving coupling (Li/THF) of diacetal bromide 4 with cyclohexanone derivative 5 followed by dehydration, ketal hydrolysis, cyclodehydration (6 -> 9) and treatment of 9 with CH3Li to give the isomers 10a-c.Cyclization (CF3CO2H/CH2Cl2) of 10a-c at -80 degC produced the tetracyclic dienes 11a/11b in the ratio 6:1, at 0 degC in the ratio 3:2.Hydrogenation at Δ20(22) of 11a and 11b, HBr induced isomerization (Δ8(14) -> Δ14) and stereoselective hydrogenation at Δ14 produced the mono-enes 16a and 16b, respectively, which were converted into the title compounds 18a and 18b.